Ads
related to: autoimmune disease that affects liver and spleen- Chronic GVHD Treatment
Learn About How a Medicine May
Be Able to Help.
- For Chronic GVHD
Discover an Option That
May Help with Scarring and Swelling
- FAQs and Resources
Find Resources and Answers
to Frequently Asked Questions.
- $0 Co-Pay
Learn How You Can Save on cGVHD
Treatment w/ our Co-Pay Program.
- Chronic GVHD Treatment
Search results
Results From The WOW.Com Content Network
Autoimmune hepatitis, formerly known as lupoid hepatitis, plasma cell hepatitis, or autoimmune chronic active hepatitis, is a chronic, autoimmune disease of the liver that occurs when the body's immune system attacks liver cells, causing the liver to be inflamed.
This article provides a list of autoimmune diseases. These conditions, where the body's immune system mistakenly attacks its own cells, affect a range of organs and systems within the body. Each disorder is listed with the primary organ or body part that it affects and the associated autoantibodies that are typically found in people diagnosed ...
The liver is enlarged (hepatomegaly) in 30–40% of patients. [citation needed] Autoimmune disease is the second most common clinical manifestation and one that most often requires treatment. The most common autoimmune presentations include autoimmune cytopenias, which can be mild to very severe and intermittent or chronic. [5]
Felty's syndrome (FS), also called Felty syndrome, [1] is a rare autoimmune disease characterized by the triad of rheumatoid arthritis, enlargement of the spleen and low neutrophil count. The condition is more common in those aged 50–70 years, specifically more prevalent in females than males, and more so in Caucasians than those of African ...
Infectious agents include viruses, bacteria, and parasites. Metabolic causes include prescription medications, toxins (most notably alcohol), and non-alcoholic fatty liver disease. Autoimmune and genetic causes of hepatitis involve genetic predispositions and tend to affect characteristic populations. [24]
This month, the FDA granted accelerated approval to Iqirvo (elafibranor) for the treatment of an autoimmune disease that can affect the liver called primary biliary cholangitis.
Ad
related to: autoimmune disease that affects liver and spleen